NMN is a precursor to NAD+ and is crucial for DNA repair, and regulating various cellular processes.
UTHEVER® NMN Phase II human clinical study confirms its benefits for sleep quality, insomnia symptoms, and fatigue. The study enrolled 34 adults aged 35–60 diagnosed with insomnia or mild sleep disorders.
PSQI sleep quality scores changed by 37%, indicating overall sleep improvement. Insomnia severity and fatigue scores dropped significantly (-48%), and continued to decline 1 month after stopping use, demonstrating sustained effects.
Download our new NAD+ Industry White Paper to explore more possibilities for NAD+-related products.
